Head- to Head Comparison of [68Ga]Ga-PSMA-11 With [18F]PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tel-Aviv Sourasky Medical Center
Age
18–120
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
1. Patients with prostate cancer, at moderate or high risk according to D'Amico classification during the staging phase,and who have not received any treatment (Gleason 7 and above and / or PSA\> 10 and / or T2c or greater disease stage).
2. . Patients who are treated in the Department of Urology at Tel Aviv Medical Center and who are undergoing Radical Prostatectomy, as a Dependent Treatment.
You may not be if
1. Patients with another malignant disease.
2. Patients under the age of 18 years.
Clareo Health | Head- to Head Comparison of [68Ga]Ga-PSMA-11 With [18F]PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard
